← All trials
NCT03612219
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2018
- Primary completion
- Jul 28, 2021
- Completion date
- Jul 28, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Guilin UniversityLead sponsor
- Guangxi Medical UniversityCollaborator
- Wuzhou Red Cross HospitalCollaborator
- Guilin UniversitySponsor investigator
- Guilin UniversityStudy director
- People's Hospital of BaiseCollaborator
- People's Hospital of LingshanCollaborator
- Guangxi Minzu HospitalCollaborator
- Laibin people's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.